|
Lucid Diagnostics, Inc. ("Lucid") is a commercial-stage medical diagnostics
technology company focused on the millions of patients with gastroesophageal
reflux disease ("GERD"), also known as chronic heartburn, acid reflux or simply
reflux, who are at risk of developing esophageal precancer and cancer,
specifically highly lethal esophageal adenocarcinoma ("EAC"). References in this
Form 10-K to "we," "us" and "our" are to Lucid and, unless the context otherwise
requires, its subsidiaries.
We believe that our lead products, the EsoGuard® Esophageal DNA Test performed
on samples collected with the EsoCheck® Esophageal Cell Collection Device,
constitute the first and only commercially available diagnostic test capable of
serving as a widespread screening tool to prevent EAC deaths, through early
detection of esophageal precancer in at-risk GERD patients.
|
|